



# ATM Mutations and Radio-sensitivity: A Review of Molecular Pathology and Cancer Susceptibility

Lisiane Cervieri Mezzomo<sup>1</sup>, Silvia Maria Spalding<sup>1</sup>, Luciane Noal Calil<sup>1</sup>, Renata Pereira Limberger<sup>1</sup> and Adelina Mezzari<sup>1</sup>

<sup>1</sup>Analysis department, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Brazil.

Received: 10 Jan 2020 / Accepted: 18 March 2020 / Published online: 01 April 2020

\*Corresponding Author Email: [lisimezzomo@gmail.com](mailto:lisimezzomo@gmail.com)

ORCID: <https://orcid.org/0000-0002-3309-247X>

## Abstract

Hereditary mutations of genes involved in DNA repair have resulted in increased susceptibility to a variety of cancers. Mutations in ataxia telangiectasia mutated (*ATM*) gene result in an autosomal recessive disorder ataxia telangiectasia syndrome (AT), which manifests with greater predisposition to various types of cancer, radiotherapy resistance and adverse prognosis. Therefore, patients with AT and their cells are radiosensitive, mainly because ATM protein kinase is a regulator of DNA damage identification and cell cycle control in response to ionizing radiation. Blood relatives of AT can also carry a pathogenic *ATM* mutation, which presents similar or even other risks (not yet completely described), although apparently healthy. Due to the unusual phenotype of radiosensitive cells in ATM patients, it has been the focus of numerous studies in the past two decades. The efficiency of radiotherapy treatment among ATM patients has been questioned due to its toxic effect on normal tissue. As certain ATM signaling provided valuable information about the response to DNA damage and cancer, but the understanding of the role of ATM in radio sensitivity is still incipient and, therefore, the molecular determinants of the clinical response are poorly understood so far. On the face of these considerations, this work presents a review of the normal structure and function of the ATM with compilation of the current literature on the risk of radio sensitivity and malignancy among patients with mutations in the ATM.

## Keywords

Ataxia Telangiectasia Mutated, *ATM*, DNA damage, DNA repair, radiation therapy, cell cycle checkpoint, cancer.

\*\*\*\*\*

## I. INTRODUCTION

Activation of checkpoint arrest and DNA repair are necessary to maintain genomic integrity during DNA replication. Defective DNA repair is seen in cancer and results in genomic instability and the accumulation of other genetic abnormalities (1, 2). Thus, cancers with mutations in the genes that encode proteins involved in DNA repair may be more

sensitive to treatments, inducing DNA damage or inhibiting complementary DNA repair mechanisms (3).

Hereditary mutations of genes involved in DNA repair, such as ataxia telangiectasia mutated (*ATM*), are causative of ataxia-telangiectasia syndrome (AT), a rare autosomal recessive systemic disorder first described more than 60 years ago(4), which result in

considerably increased susceptibility to a variety of malignancies, ranging from 10% to 20% (5, 6). Cancer types risk includes lymphoid, gastric, breast, central nervous system, skin, and others. In addition, progressive cerebellar ataxia, immunological defects, insulin-resistant diabetes and radiosensitivity can occur in this patient characterized by biallelic mutations in the *ATM* gene. Besides that, a large number of mutations (more than 600) can occur in the *ATM* coding and noncoding regions (7), and the patient's response varies depending on the type of mutation. *ATM* protein kinase is involved in many cellular functions, including response to DNA damage, control of the cell cycle checkpoint, apoptosis (8) oxidative stress and mitochondrial metabolism (9). It integrates the cellular response to damage by phosphorylation of the main proteins involved in cell cycle regulation and DNA repair and, therefore, lack of normal *ATM* function in inherited AT syndrome results in a pleiotropic clinical syndrome characterized not only by a marked increase in the risk of cancer but also profound hypersensitivity to ionizing radiation. Cells derived from patients with AT presents genomic instability, loss of normal cell cycle arrest pathways, defects in DNA repair and increased sensitivity to radiation. These mechanisms indicate the *ATM* play an important role in maintaining genomic integrity and, therefore, in the mechanism of cancers pathogenesis (10, 11).

*ATM* is a gene known to be associated with radiosensitivity in the germ line, studies show that its inhibition increases the sensitivity of cancer cells to radiotherapy, one of the most frequently used treatments for different types of cancer, in order to eliminate the cells tumors, but the molecular determinants and clinical response in *ATM* patients are still poorly understood (12). In this sense, this narrative review aims to provide an overview in order to outline the current understanding of the predictive potential of *ATM* gene mutation to respond to the risk of radiation toxicity and radiation therapy, as well as the susceptibility to cancer among patients with AT mutations.

## II. RESULTS AND DISCUSSION

### Structure and functions of *ATM*

The *ATM* gene was first identified in 1995 through studies of AT syndrome (13). It locates in the human chromosome 11q22-23, includes 66 exons with a 9168-base pair. *ATM* is a powerful protein kinase, member of the phosphatidylinositol 3 (PI3K) like protein kinase (PIKK) family, that encodes a human PI3K serine/threonine PIKK that helps maintain

genomic integrity (14). This protein is involved in a multitude of cellular processes. It has been well described that it plays an important role in the normal development and activity of body systems, including the nervous and immune systems. It also attends to cells in recognizing damaged or broken DNA strands. In this context, it plays a central role in the repair of DNA double-strand breaks (DSB), which can be induced by several mechanisms, including: ionizing radiation, chemotherapy drugs, or oxidative stress, or even occur during normal physiologic events like meiotic recombination or rearrangement of antibody genes during B-cell maturation (15, 16). It is a consensus within the scientific community that *ATM* has extensive roles in DNA damage response signaling, and plays a critical role in the signal transduction of cell cycle checkpoint, the repair of damaged DNA and the apoptosis (14). Some authors report that *ATM* is a master regulator of DNA damage response (17).

The *ATM* protein location is predominantly nuclear in most cell types (where it exists as a non-covalent homodimer) and also in subcellular organelles. This form of protein is catalytically inactive in the resting state cells, but with DNA damage it is rapidly activated and converts to an active monomer from that phosphorylates a large number of substrates involved in a diverse array of cellular process, like cell cycle checkpoints and DNA repair (18). Thus, *ATM* responds locally to specific DNA damage, phosphorylating the main substrates involved in DNA repair and/or the cell cycle control (14).

Once activated (when DNA damage is detected), *ATM* phosphorylates a large number of downstream effectors, which then phosphorylate its own targets. It has been described that there are more than 700 targets after DSBs and also that *ATM* modulates networks that are not immediately involved in DNA repair, such as the insulin-like growth factor or other metabolic and stress-response pathways (19). The abundance of *ATM* targets are probably a means of coordinating several pathways in the event of DNA repair or genomic stress (20).


Considerable progress has been achieved in delineating the role of *ATM* in controlling the cell cycle checkpoint, given the large number of researches in this field. However, the focus of current research is the relationship between *ATM* and signaling pathways in certain events, such as type of tumors and sensitivity to radiation/radiation treatment in these events, as well as personalized pharmacological treatments in AT patients. The central question here seems to be what the best

therapeutic approach is to be indicated for these patients.

### III. The role of ATM in damage response induced by radiation

Cell cycle checkpoints are crucial and can improve cell expansion and limit mutagenic events after DNA

damage. It is already known that ATM mediated signaling pathways (Figure 1) play an essential role in the responses of the checkpoint of the radiation-induced cell cycle, such as that induced by ionizing radiation (21).



**Figure 1: Model to explain the role of ATM in DNA damage response. ATM maintains the DNA integrity and, consequently, genomic stability, activating multiple cellular functions. A defect in the ATM leads to abnormal responses to DNA damage and consequently to cancer susceptibility.**

In response to radiation-induced DNA-damage, ATM kinases are activated quickly, which in turn triggers phosphorylation of their respective downstream targets, including p53, kinesin-associated kap-1 protein (KAP-1), as well as the checkpoint kinases 1 (CHK1) and 2 (CHK2) (13, 22), two serine/threonine protein kinases (Ser/Thr), that play an important role in the regulation of the cell cycle and in the phosphorylation of p53, which plays an important role in the control of the cell cycle and in apoptosis. The activation of CHK1 and CHK2 results in phosphorylation of Cdc25, leading to sequestration, degradation and / or subcellular inhibition (inhibitory phosphorylation) that normally activates Cdc2 / cyclin B at the G2 / M limit (23). CHK2 can also phosphorylate p53-Ser20 to bring stabilization of the p53 protein after radiation. The activation of p53 by ATM, ATR and CHK2 kinases leads to the induction of p21 protein, which can directly inhibit the activity of the Cdc2 / Cyclin B complex, which governs entry into mitosis (22). Additional evidence supports a direct role of ATM in other checkpoints of the cell cycle, which includes c-Abl, a protein tyrosine kinase, and beta-adaptin, an endosomal protein, among others (24).

This activation lead to cell cycle checkpoints, arrests and delays in the G1, S, and G2 phases of the cell cycle and even allows DNA repair of double-strand breaks, both by homologous recombination and by non-homologous final union (15, 16). The G1/S interface ATM has been shown to play a central role in radiation-induced activation of the p53 tumour suppressor gene product, since ATM binds to p53 in a complex way and activates the molecule in response to breaks in DNA. The signaling pathways of the radiation-induced cell cycle checkpoint promote cell cycle arrest, which, in turn, contributes positively to cell survival in response to this event (8, 25). Therefore, ATM levels are not altered after exposure to ionizing radiation, but ATM kinase activity increases after exposure several times (21).

Cells of patients with AT syndrome fail to show initial delay at several checkpoints of the cell cycle after irradiation. In addition, a defect in the induction of p53 by ionizing radiation was evident in these patients. In this sense, the ATM gene mutation leads to the functional and structural alteration of the ATM protein in the these patients, leading to the occurrence of abnormalities in the cell cycle checkpoint and DNA damage repair, leading to an increase in sensitivity to apoptosis. The *ATM* gene

mutated production the human genetic disorder AT is a 350 kDa protein that plays a central role in the regulation of several cellular processes. Therefore, defects are observed at all cell cycle checkpoints in post-irradiation AT cells (26, 27).

It is likely that environmental radiation exposure may have a greater effect on certain ATM genotypes / variants and may induce different modifications in cellular responses in these patients. In this case, the importance of radiation exposure as a risk factor must be examined in epidemiological analyses stratified by genotype (28).

### **ATM and Radiosensitivity**

ATM is described as one of the main regulators of the cellular response to radiation-induced DNA damage and a key determinant of radiosensitivity (28). This evidence has been demonstrated by several previous studies that have shown a leading role for ATM kinase in the regulation of cancer cell radioresistance (29, 32)

On the other side, radiation therapy is an approach to cancer treatment that has unquestionably significantly improved the local control of the disease and the overall survival of cancer patient. In general, radiation hinders the growth of cancer cells by inducing cytotoxicity, caused mainly by DNA damage (29).

DNA damage induced by ionizing radiation can significantly affect whether a cell will proliferate, differentiate, become senescent, or go into apoptosis (30, 31). In general cellular properties (such as cell type and tissue of origin) determined the DNA damage associated cell-fate decisions (32). Even the physiological properties of the cells, including the ability to detect, repair, and tolerate DNA damage, are likely to be important determinants of fate when cells are exposed to varying degrees of DNA damage (33).

In addition, the amount and quality of DNA damage also affects these decisions about the fate of cells. Thus, the dose rate of sparingly ionizing radiation is particularly important, since lower dose rates produce smaller biological effects, even when the total dose is kept constant (34). Hickson and cols (24) confirm these data and suggest that inhibition of ATM should radiosensitize tumors. They showed that fibroblasts and tumor cells are radiosensitized to X-ray radiotherapy (XRT) in culture by pharmacological ATM inhibition, or by ATM mutation and deletions (35). However, caution is needed when using this strategy clinically, due to the possibility that normal tissues may also be sensitized as well. This reluctance is well founded, as it is based on the

previous dire response of patients with AT to XRT already described.

Thus, cells harboring loss-of function ATM deficiencies demonstrate extreme radio sensitivity. Further, AT syndrome is often referred to as a genome instability or DNA damage response syndrome. For this reason, the efficiency of radiotherapy has been considered very limited in patients with biallelic mutations or deletions of ATM due to its toxic effect on normal tissue (36).

Cao and cols (33) have been demonstrated a critical role for the ATM tumor protein p53 (TP53)/p21 pathway in the regulation of DNA-damage-associated cell fate. Cultured mouse cells were exposed to various amounts and qualities of <sup>137</sup>Cs  $\gamma$ -irradiation and then and then the effects of this irradiation on different types of human cells were monitored. The researchers showed that inhibition of ATM/TP53/p21 complex change the responses to DNA damage, leading to micronucleus formation in chronically irradiated cells, the measure of which assesses genomic instability. In addition, the study clearly demonstrated that the ATM/TP53/p21 pathway regulates the relationship between DNA-damage tolerance and response when cells were exposed to chronic  $\gamma$ -irradiation and that this decision depended on the dose rate and the cell type. The TP53 pathway was a critical component of cellular responses to chronic  $\gamma$ -irradiation, which were triggered by the rate of DNA damage.

A recently published study evaluated whether radiation therapy affects contralateral breast cancer risk in women with ATM pathogenic germline variants (among others) in breast cancer. This study described that rare ATM missense variants, currently not identified as pathogenic, were associated with risk of radiotherapy(37).

It is very important to identify the critical determinants of radioresistance and to develop safe and effective tumor radiosensitizers, especially considering patients with ATM gene deficiencies. Thus, taking these processes into account, there is still an extensive field of research for the development of ATM inhibitors (ATMi) as anticancer agents (38).

### **ATM mutations and malignancy risk**

The ATM gene is mutated in the autosomal recessive disorder, AT syndrome, characterized by an increased risk of susceptibility to cancer throughout life (39, 40), and may be related to the radiosensitivity, resulting in chromosomal and chromatid breaks.

The types tumors are diverse in patients with AT. Previous data indicate a high incidence of lymphoid neoplasms, most notably T-cell acute lymphoblastic leukemias. Recently, B-cell non-Hodgkin's lymphoma and Hodgkin's lymphoma was also reported to be more frequent than initially recognized. Patients with AT also develop carcinoma, but less frequently and at an older age than lymphoid cancers (40-42). Another category, AT mutation carriers, are generally healthy individuals who have a mutated copy of the *ATM* gene, such as the parents or other blood relatives of a person with AT syndrome. However, a systematic meta-analysis found that patients with *ATM* mutation have a short lifespan due to cancer (breast and gastrointestinal tract) and ischemic heart disease (43).

More than 400 disease-related mutations have been described in *ATM* gene, which may be due to mutations in a homozygous or compound heterozygous germline. *ATM* mutations identified in AT families can be divided in three categories; truncating mutations, mutations that lead to some expression of mutant protein that does not have kinase activity and missense mutations with reduced kinase activity(44). Approximately 70% of the disease-related mutations result in the production of truncated protein (45).

*ATM* carriers who are heterozygous for *ATM* gene variants are often asymptomatic and largely considered healthy carriers. Despite this, it has been described that they are more sensitive to ionizing radiation and susceptible to ischemic heart disease, diabetes, and cancer, specially breast cancer, and that of digestive tract, lung and lymphoid origin (46, 47).

Monoallelic *ATM* mutation carriers are also at risk of malignancy, particularly breast cancers, and many association studies have been conducted on breast cancer susceptibility. Initially, epidemiological studies on relatives of AT patients revealed a two to five-fold increase in the risk of breast cancer for female obligate *ATM* carriers (20, 48, 49).

*ATM* mutations are associated with an increase of approximately two to three times the risk of breast cancer, however, for patients with a familial history of the disease, risk estimates increase even more, which is probably due to other risk increasing variants in the families (50, 51). The increased risk of breast cancer in patients with *ATM* was confirmed by direct *ATM* sequencing in breast cancer cases compared to controls(49). *ATM* is also considered a moderate-penetrance cancer susceptibility gene in *BRCA1/2*-negative patients with familial early-onset breast cancer (52).

Another recently published study (53) evaluated deleterious germline mutations in *ATM* by PCR-Sanger sequencing 7657 in *BRCA1/2* negative breast cancer patients and founded 31 pathogenic mutations in the *ATM* gene across 30 carriers. The *ATM* mutation rate was 0.4% (30/7.657). Those patients were significantly more likely to have family history of breast and/or ovarian cancer (26.7% in carriers vs. 8.6% in non carriers). Another study corroborates these data when using the multigenic panel by next generation sequencing method to identify that *ATM* was mutant in non-*BRCA1/2* patients with hereditary risk of breast cancer (54).

Next-generation sequencing has led to the recent discovery that pathogenic *ATM* variants are often identified in patients with pancreatic ductal adenocarcinoma with and without a family history of the disease. In addition, it was described that the loss of *ATM* was also a frequent somatic event in the development of these type of cancer (55). *ATM* was recently described using a complete exome sequencing technique as one of the most frequently mutated germline genes in aggressive prostate cancer (56). Another molecular method was used to evaluate the relation between *ATM* polymorphism and gastric cancer in the Chinese population. The study found that the *ATM* polymorphism was related to increased susceptibility and worse prognosis (57). Along with mutations associated with AT, several *ATM* examinations in cancer patients have identified missense *ATM* variants, particularly amino acid substitutions that are not expected to be associated with AT (58). However, discrimination of these *ATM* variants from *ATM* polymorphisms and their contribution to health risks is still controversial (59).

A national cohort study carried out in the registry of the French National Reference Center for Primary Immune Deficiencies (CEREDIH), conducted by Suarez and cols (40) evaluated retrospectively the incidence of cancer in 279 patients with AT syndrome. The follow-up of patients with AT with malignant neoplasms was 13.9 years and the incidence of malignancy was 24.7% among them (1,571 events per 100,000 person-years) and did not vary across decades. The median age at diagnosis of malignancy of any type was 12.5 years and differed significantly across the groups of tumors (an average age of onset of Hodgkin's lymphoma is 10.6 years old and carcinomas, 31 years old). Lymphoid neoplasms, particularly acute lymphoblastic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma, represented the majority of cancers. The study (40) showed that the cumulative incidence of cancer was 10.4% at 10 years, 22.6% at 20 years, 29.9% at 30 years, and 38.2% at 40 years. By age 10 years, 1.9%

of patients had developed lymphoblastic leukemia, 2.3% Hodgkin's lymphoma, and 6.2% non-Hodgkin's lymphoma. At 20 years of age, 3.5% of patients developed acute lymphoblastic leukemia, 5.5% Hodgkin's lymphoma, and 13.6% non-Hodgkin's lymphoma. No patient developed acute lymphoblastic leukemia or Hodgkin's lymphoma after age 20 years. At age 30, 17.6% of patients developed non-Hodgkin's lymphoma, 2.6% T-PLL and 0.8% a solid tumor. At 40 years of age, 20% of patients developed non-Hodgkin's lymphoma and 6.6% a solid tumor (40). This study also showed that solid cancers (such as breast, gastric, liver, and thyroid) comprised mostly carcinomas.

The patient's family and personal history is important for identifying and diagnosing tumors. In a retrospective study of 279 patients with AT syndrome, 69 had cancer and most were hematological cancers, including the majority as 38 cases of non-Hodgkin's lymphoma (60)

Although the precise mechanisms of malignancy in AT are not fully understood, it is considered to be primarily related to the role of ATM in maintaining genomic stability. However, the exact contributions of the various ATM functions, the immunodeficiency associated with AT and possible extrinsic factors remain unclear until now. Immunodeficiency associated with AT is variable, and its causal relationship with the development of cancer is questioned (17, 38).

### III. CONCLUSION

Considering the unusual radiosensitive phenotype of cells from AT patients, ATM has been the focus of intense scrutiny for the past two decades. In order to improve the efficacy of radiation therapy in AT carriers, it is necessary a better understanding of the signaling network that drives ATM mutated cell to be cancerous and then to overcome radiation-induced cytotoxicity.

The treatment of ATM mutations in cancer patients is challenging, because the impact of antineoplastic treatment on response and toxicity is not well established. Survival after cancer is considered short in TA patients, but long-term remissions are possible. The risk of second neoplasms is still not well established in these patients, and there is no consensus in the scientific community. Recognition of clinical and biological heterogeneity in the ATM mutation, both for AT syndrome and for AT carriers, is thought to be at least in part associated with the type of ATM mutations, and patients with loss of function mutations appear to have different susceptibility cancer and different survival rates.

The identification of patients with a mutable or pathogenic ATM variant of the germ line and, therefore, a greater susceptibility to the development of some types of cancer, is essential for the early detection that is advocated in improving patient care, detecting cancer before metastases, contributing to the improvement of the patient's prognosis and life expectancy.

Despite the great efforts of the scientific community, we can conclude that there is a great gap with regard to the therapeutic conduct of ATM patients. Well-designed studies are still needed to contribute to a better understanding of cancer susceptibility in AT patients, and its relationship with radio sensitization, in addition to ATM-mediated signaling, to cause cells to stop the cycle and start DNA repair. The analysis of these genotypes can eventually be applied clinically to determine treatment modalities in affected patients. Taken together, targeting ATM in association with another genetic panel can be a promising strategy for cancer treatment.

### REFERENCES

1. Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. *Annual review of pathology* 2015; 10, 425-448.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144, 646-674.
3. Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what's new? *Future Oncol* 2014; 10, 1215-1237.
4. Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. *Pediatrics* 1958; 21, 526-554.
5. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. *Journal of the National Cancer Institute* 1986; 77, 89-92.
6. Peterson RD, Kelly WD, Good RA. Ataxia-Telangiectasia. Its Association with a Defective Thymus, Immunological-Deficiency Disease, and Malignancy. *Lancet* 1964; 1, 1189-1193.
7. Campbell C, Mitui M, Eng L, Coutinho G, Thorstenson Y, Gatti RA. ATM mutations on distinct SNP and STR haplotypes in ataxia-telangiectasia patients of differing ethnicities reveal ancestral founder effects. *Human mutation* 2003; 21, 80-85.
8. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nature reviews Molecular cell biology* 2013; 14, 197-210.
9. Kamsler A, Daily D, Hochman A, Stern N, Shiloh Y, Rotman G, Barzilai A. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. *Cancer research* 2001; 61, 1849-1854.

10. Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. *Blood* 2013; 121, 4036-4045.
11. McKinnon PJ. ATM and ataxia telangiectasia. *EMBO reports* 2004; 5, 772-776.
12. Ma J, Setton J, Morris L, Albornoz PB, Barker C, Lok BH, Sherman E, Katabi N, Beal K, Ganly I, Powell SN, Lee N, Chan TA, Riaz N. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM. *Oncotarget* 2017; 8, 10312-10323.
13. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NG, Taylor AM, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science* 1995; 268, 1749-1753.
14. Cremona CA, Behrens A. ATM signalling and cancer. *Oncogene* 2014; 33, 3351-3360.
15. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annual review of biochemistry* 2010; 79, 181-211.
16. Bednarski JJ, Sleckman BP. Integrated signaling in developing lymphocytes: the role of DNA damage responses. *Cell cycle* 2012; 11, 4129-4134.
17. Lee JH, Mand MR, Kao CH, Zhou Y, Ryu SW, Richards AL, Coon JJ, Paull TT. ATM directs DNA damage responses and proteostasis via genetically separable pathways. *Science signaling* 2018; 11.
18. Paull TT. Mechanisms of ATM Activation. *Annual review of biochemistry* 2015; 84, 711-738.
19. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lereenthal Y, Shiloh Y, Gygi SP, Elledge SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 2007; 316, 1160-1166.
20. Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. *Molecular cancer therapeutics* 2016; 15, 1781-1791.
21. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. *Science* 1998; 281, 1677-1679.
22. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. *Annual review of biochemistry* 2004; 73, 39-85.
23. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. *Nature* 2004; 432, 316-323.
24. Lavin MF, Khanna KK. ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia. *International journal of radiation biology* 1999; 75, 1201-1214.
25. Nakamura Y. ATM: the p53 booster. *Nature medicine* 1998; 4, 1231-1232.
26. Khanna KK, Beamish H, Yan J, Hobson K, Williams R, Dunn I, Lavin MF. Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. *Oncogene* 1995; 11, 609-618.
27. Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. *Cell cycle* 2010; 9, 472-478.
28. Khanna KK. Cancer risk and the ATM gene: a continuing debate. *Journal of the National Cancer Institute* 2000; 92, 795-802.
29. Hein AL, Ouellette MM, Yan Y. Radiation-induced signaling pathways that promote cancer cell survival (review). *International journal of oncology* 2014; 45, 1813-1819.
30. Smith LE, Nagar S, Kim GJ, Morgan WF. Radiation-induced genomic instability: radiation quality and dose response. *Health physics* 2003; 85, 23-29.
31. McMillan TJ. Residual DNA damage: what is left over and how does this determine cell fate? *European journal of cancer* 1992; 28, 267-269.
32. Panganiban RA, Snow AL, Day RM. Mechanisms of radiation toxicity in transformed and non-transformed cells. *International journal of molecular sciences* 2013; 14, 15931-15958.
33. Cao L, Kawai H, Sasatani M, Iizuka D, Masuda Y, Inaba T, Suzuki K, Ootsuyama A, Umata T, Kamiya K, Suzuki F. A novel ATM/TP53/p21-mediated checkpoint only activated by chronic gamma-irradiation. *PLoS one* 2014; 9, e104279.
34. Hall EJ, Bedford JS. Dose Rate: Its Effect on the Survival of HeLa Cells Irradiated with Gamma Rays. *Radiation research* 1964; 22, 305-315.
35. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GC. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. *Cancer research* 2004; 64, 9152-9159.
36. Ahmed M, Li L, Pinnix C, Dabaja B, Nomie K, Lam L, Wang M. ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. *Critical reviews in oncology/hematology* 2016; 107, 14-19.
37. Reiner AS, Robson ME, Mellekjaer L, Tischkowitz M, John EM, Lynch CF, Brooks JD, Boice JD, Knight JA, Teraoka SN, Liang X, Woods M, Shen R, Shore RE, Stram DO, Thomas DC, Malone KE, Bernstein L, Riaz N, Woodward W, Powell S, Goldgar D, Concannon P, Group WSC, Bernstein JL. Radiation treatment, ATM, BRCA1/2, and CHEK2\*1100delC pathogenic variants, and risk of contralateral breast cancer. *Journal of the National Cancer Institute* 2020.
38. Tang S, Li Z, Yang L, Shen L, Wang Y. A potential new role of ATM inhibitor in radiotherapy: suppressing ionizing Radiation-Activated EGFR. *International journal of radiation biology* 2020; 96, 461-468.
39. Reiman A, Srinivasan V, Barone G, Last JI, Wootton LL, Davies EG, Verhagen MM, Willemsen MA, Weemaes CM, Byrd PJ, Izatt L, Easton DF, Thompson DJ, Taylor AM. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood

- tumours. *British journal of cancer* 2011; 105, 586-591.
40. Suarez F, Mahlaoui N, Canioni D, Andriamanga C, Dubois d'Enghien C, Brousse N, Jais JP, Fischer A, Hermine O, Stoppa-Lyonnet D. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2015; 33, 202-208.
  41. Carine AM Tasso ALFDLF, Joyce Bonazzoni, Simone, Krause Ferrão LNC, Adelina Mezzari, Renata Pereira Limberger. Mutated Ataxia-Telangiectasia and Its Correlation with the Incidence of Neoplasms: A Literature Review. *IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS)* 2018; 13, 8.
  42. André Luiz Freitas De Lima Filho CAT, Lisiane Cervieri Mezzomo, Silvia, Maria Spalding LNC, Renata Pereira Limberger, and Adelina Mezzari. 20 years after the first report of the need for laboratory Clinical tracking of Ataxia-Telangiectasia Mutated (ATM) as a Strategy in therapeutic management, a literature review. *World Journal of Pharmaceutical and Medical Research* 2019; 5, 6.
  43. van Os NJ, Roeleveld N, Weemaes CM, Jongmans MC, Janssens GO, Taylor AM, Hoogerbrugge N, Willemsen MA. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. *Clinical genetics* 2016; 90, 105-117.
  44. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. *Breast cancer research and treatment* 2008; 107, 243-248.
  45. Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. *Human mutation* 1997; 10, 100-107.
  46. Su Y, Swift M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. *Annals of internal medicine* 2000; 133, 770-778.
  47. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R, Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, Papadopoulos N, Hruban RH, Kinzler KW, Klein AP. ATM mutations in patients with hereditary pancreatic cancer. *Cancer discovery* 2012; 2, 41-46.
  48. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. *The New England journal of medicine* 1987; 316, 1289-1294.
  49. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Breast Cancer Susceptibility C, Easton DF, Stratton MR, Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nature genetics* 2006; 38, 873-875.
  50. Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Butzow R, Blomqvist C, Aittomaki K, Nevanlinna H. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. *International journal of cancer* 2019; 145, 2692-2700.
  51. Luciane Noal Calil ALFDLF, Simone Krause Ferrão, Joyce Bonazzoni,, Carine AM Tasso VZB, Renata Pereira Limberger, Adelina Mezzari. The importance of the diagnosis of the ATM gene (Ataxia Telangiectasia Mutated) in patients with hereditary pre-disposition to breast cancer; narrative literature review. *World Journal of Pharmaceutical and Medical Research* 2018; 4, 4.
  52. Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. *Genetics in medicine: official journal of the American College of Medical Genetics* 2015; 17, 630-638.
  53. Yang Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Zhang J, Xie Y. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients. *Breast cancer research and treatment* 2019; 174, 639-647.
  54. Li JY, Jing R, Wei H, Wang M, Xiaowei Q, Liu H, Jian L, Ou JH, Jiang WH, Tian FG, Sheng Y, Li HY, Xu H, Zhang RS, Guan AH, Liu K, Jiang HC, Ren Y, He JJ, Huang W, Liao N, Cai X, Ming J, Ling R, Xu Y, Hu CY, Zhang J, Guo B, Ouyang L, Shuai P, Liu Z, Zhong L, Zeng Z, Zhang T, Xuan Z, Tan X, Liang J, Pan Q, Chen L, Zhang F, Fan LJ, Zhang Y, Yang X, BoLi J, Chen C, Jiang J. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. *International journal of cancer* 2019; 144, 281-289.
  55. Nanda N, Roberts NJ. ATM Serine/Threonine Kinase and its Role in Pancreatic Risk. *Genes* 2020; 11.
  56. Rantapero T, Wahlfors T, Kahler A, Hultman C, Lindberg J, Tammela TL, Nykter M, Schleutker J, Wiklund F. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. *Genes* 2020; 11.
  57. Tao Y, Mei Y, Ying R, Chen S, Wei Z. The ATM rs189037 G>A polymorphism is associated with the risk and prognosis of gastric cancer in Chinese individuals: A case-control study. *Gene* 2020; 741, 144578.
  58. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. *Molecular genetics and metabolism* 1999; 68, 419-423.
  59. Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, Coppa A, Sciacchitano S, Giordano C, Pinnaro P, Sanguineti G, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado G, Vizza E, Giannini G, Soddu S. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.





Journal of experimental & clinical cancer research:  
CR 2016; 35, 135.

60. Ye F, Chai W, Yang M, Xie M, Yang L. Ataxia-telangiectasia with a novel ATM gene mutation and

Burkitt leukemia: A case report. *Molecular and clinical oncology* 2018; 9, 493-498.